World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
46125
World Ranking
11097
National Ranking
5710

Overview

Christian Jackisch is affiliated with the Breast Cancer Research Foundation in the United States. Their research predominantly focuses on oncology, with significant contributions in breast cancer treatment studies and cancer research. Their work extends into related subfields including pulmonary and respiratory medicine, genetics, and pathology and forensic medicine.

The main fields of study associated with their research are medicine and biochemistry, genetics, and molecular biology. Key subfields where they have published include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Pathology and Forensic Medicine

Their research addresses various topics, with the most frequent areas being:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Breast Lesions and Carcinomas
  • Cancer Genomics and Diagnostics

Christian Jackisch has published articles extensively in several scientific journals. The most frequent publication venues include:

  • Annals of Oncology
  • Cancer Research
  • Geburtshilfe und Frauenheilkunde
  • Breast Care
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie

Their recent papers reflect ongoing engagement with breast cancer and oncology topics. Selected publications include:

  • "Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials" (2021, The Lancet Oncology)
  • "An Overview of PARP Inhibitors for the Treatment of Breast Cancer" (2021, Targeted Oncology)
  • "Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo" (2020, Annals of Oncology)
  • "Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response" (2022, Annals of Oncology)
  • "Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial" (2020, The Lancet Oncology)

Frequent collaborators of Christian Jackisch include:

  • Peter A. Fasching
  • Andreas Schneeweiß
  • Michael Untch
  • Sibylle Loibl
  • Carsten Denkert

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

    Andreas du Bois;Hans-Joachim Lück;Werner Meier;Hans-Peter Adams

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

    Jacobus Pfisterer;Marie Plante;Ignace Vergote;Andreas du Bois

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

    Luca Gianni;Urania Dafni;Richard D Gelber;Evandro Azambuja

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial

    Aron Goldhirsch;Richard D. Gelber;Martine J. Piccart-Gebhart;Evandro De Azambuja

  • A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

    S. Loibl;M. Untch;N. Burchardi;J. Huober

  • Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

    Gunter von Minckwitz;Holger Eidtmann;Mahdi Rezai;Peter A. Fasching

  • Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group

    Gunter von Minckwitz;Günter Raab;Angelika Caputo;Martin Schütte

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

    Evandro De Azambuja;Andrew P. Holmes;Martine Piccart-Gebhart;Eileen Holmes

  • Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

    David Cameron;Julia Brown;Rebecca Dent;Christian Jackisch

  • Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

    Michael Untch;Sibylle Loibl;Joachim Bischoff;Holger Eidtmann

Frequent Co-Authors

Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Jens Huober
Jens Huober Kantonsspital St. Gallen
Carsten Denkert
Carsten Denkert Philipp University of Marburg
Jens-Uwe Blohmer
Jens-Uwe Blohmer Charité - University Medicine Berlin
Christoph Thomssen
Christoph Thomssen University of Göttingen
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a medical career but want flexible education options, there are many online programs tailored to different goals. For nurses, advancing your qualifications is often key. Those looking for affordable ways to earn their BSN can explore the cheapest rn to bsn program online options, which help registered nurses obtain bachelor’s degrees at lower costs.

If you have a non-nursing background but wish to pursue nursing, online direct entry msn programs for non-nursing majors allow qualified students to transition into the field efficiently. Applicants seeking accessible admissions can also benefit from research on the easiest nursing schools to get into, which highlights schools with flexible prerequisites.

For those interested in healthcare but not direct patient care, medical billing and coding is another rewarding pathway. Accredited distance programs, such as accredited medical billing and coding schools with financial aid, make it possible to start this career while managing costs.

Best Scientists Citing Christian Jackisch

Trending Scientists

Recently Published Articles